Colchicine for acute gout

Schlesinger, Naomi; Schumacher, Ralph; Catton, Michelle; Maxwell, Lara

doi:10.1002/14651858.cd006190

Cited by 60 publications

(47 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Colchicine effectively inhibits cell growth, mitosis [81], secretion, cell elongation, and cell motility. This MTA has been used to treat gout for more than 2,000 years, and pseudo-gout and Familial Mediterranean Fever (FMF) for several decades [82,83], but its high toxicity at doses necessary for antitumor effects have impaired any anticancer therapy development. Substoichiometric concentrations of colchicine promote inhibition of microtubule assembly.…”

Section: Is Affinity Improvement a Real Benefit?mentioning

confidence: 99%

Microtubule targeting agents: from biophysics to proteomics

Calligaris

Verdier-Pinard

Devred

et al. 2010

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

This review explores various aspects of the interaction between microtubule targeting agents and tubulin, including binding site, affinity, and drug resistance. Starting with the basics of tubulin polymerization and microtubule targeting agent binding, we then highlight how the three-dimensional structures of drug-tubulin complexes obtained on stabilized tubulin are seeded by precise biological and biophysical data. New avenues opened by thermodynamics analysis, high throughput screening, and proteomics for the molecular pharmacology of these drugs are presented. The amount of data generated by biophysical, proteomic and cellular techniques shed more light onto the microtubule-tubulin equilibrium and tubulin-drug interaction. Combining these approaches provides new insight into the mechanism of action of known microtubule interacting agents and rapid in-depth characterization of next generation molecules targeting the interaction between microtubules and associated modulators of their dynamics. This will facilitate the design of improved and/or alternative chemotherapies targeting the microtubule cytoskeleton.

show abstract

Section: Is Affinity Improvement a Real Benefit?mentioning

confidence: 99%

Microtubule targeting agents: from biophysics to proteomics

Calligaris

Verdier-Pinard

Devred

et al. 2010

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

show abstract

“…15) Long-term colchicine treatment in patients with hepatic fibrosis appeared to exert an anti-inflammatory, anti-fibrotic and immunomodulatory effects. 16) It was reported that colchicine could reduce liver fibrosis by inhibiting collagen secretion, as well as increasing collagen degradation.…”

mentioning

confidence: 99%

Combination Therapy with Taurine, Epigallocatechin Gallate and Genistein for Protection against Hepatic Fibrosis Induced by Alcohol in Rats

Zhuo

Liao

et al. 2012

Biological & Pharmaceutical Bulletin

View full text Add to dashboard Cite

This study was to investigate the possibility of enhancing the anti-fibrotic effect by using a combination therapy with taurine, epigallocatechin gallate and genistein in a rat liver fibrosis model induced by alcohol, and to explore its underlying mechanism. Hepatic fibrosis was induced by intragastric administration with various amount of alcohol (5.0-9.5 g/kg) within 24 weeks in rats. The model group received alcohol only, and treatment groups received the corresponding drugs plus alcohol respectively, while the normal control group received an equal volume of saline. The antifibrotic effects of combination therapy were assessed directly by hepatic histology, and indirectly by measurement of serum biochemical markers, the fibrosis markers and related key cytokines/proteins. The results showed that combination therapy could significantly improve the liver function, as indicated by decreasing levels of alanine transaminase, aspartate transaminase, alkaline phosphatase, γ-glutamyltransferase, interleukin-6 and tumor necrosis factor-α. Moreover, combination therapy could effectively suppress the serum levels of fibrosis markers and hepatic hydroxyproline content, inhibit collagen deposition and reduce the pathological tissue damage. Research on mechanism showed that combination therapy was able to markedly reduce lipid peroxidation and recruit the anti-oxidative defense system, and inhibit the expression of B-cell lymphoma 2, α-smooth muscle actin, transforming growth factor β 1 and small mothers against decapentaplegic homolog 3 proteins. Our results showed that combination therapy is effective in attenuating hepatic injury and fibrosis in the alcohol-induced rat model. The improved efficacy of the combination therapy with its good safety profile could represent a new protective approach for liver fibrosis.

show abstract

“…The review items on which to search for evidence were identified by the experts through a process of consensus with the aim of answering questions deemed relevant from a clinical perspective in the management of the patient with gout. New evidence on the preestablished items has been systematically collected via the Cochrane methodology utilising the same bibliographic research strategy of the EULAR recommendations, and integrating them with other strategies from Cochrane systematic reviews (85,86). Such approach guarantees both consistency with the previously collected data and the required systematic methodology for the update with new evidence.…”

Section: Strength Of Recommendation (95% Ci): 87 (81 93)mentioning

confidence: 99%

Italian Society of Rheumatology recommendations for the management of gout

et al. 2013

View full text Add to dashboard Cite

summary Objective: Gout is the most common arthritis in adults. Despite the availability of valid therapeutic options, the management of patients with gout is still suboptimal. The Italian Society of Rheumatology (SIR) aimed to update, adapt to national contest and disseminate the 2006 EULAR recommendations for the management of gout. Methods: The multidisciplinary group of experts included rheumatologists, general practitioners, internists, geriatricians, nephrologists, cardiologists and evidence-based medicine experts. To maintain consistency with EULAR recommendations, a similar methodology was utilized by the Italian group. The original propositions were translated in Italian and priority research queries were identified through a Delphi consensus approach. A systematic search was conducted for selected queries. Efficacy and safety data on drugs reported in RCTs were combined in a meta-analysis where feasible. The strength of recommendation was measured by utilising the EULAR ordinal and visual analogue scales. Results: The original 12 propositions were translated and adapted to Italian context. Further evidences were collected about the role of diet in the non-pharmacological treatment of gout and the efficacy of oral corticosteroids and low-dose colchicine in the management of acute attacks. Statements concerning uricosuric treatments were withdrawn and replaced with a proposition focused on a new urate lowering agent, febuxostat. A research agenda was developed to identify topics still not adequately investigated concerning the management of gout. Conclusions: The SIR has developed updated recommendations for the management of gout adapted to the Italian healthcare system. Their implementation in clinical practice is expected to improve the management of patients with gout.

show abstract

Colchicine for acute gout

Cited by 60 publications

References 16 publications

Microtubule targeting agents: from biophysics to proteomics

Microtubule targeting agents: from biophysics to proteomics

Combination Therapy with Taurine, Epigallocatechin Gallate and Genistein for Protection against Hepatic Fibrosis Induced by Alcohol in Rats

Italian Society of Rheumatology recommendations for the management of gout

Contact Info

Product

Resources

About